Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Director Mortimer J. Buckley acquired 1,386.834 phantom stock units as deferred compensation, increasing his total beneficial ownership to 16,704.585 units.

Summary

• Mortimer J. Buckley, a Director of Pfizer Inc. (PFE), acquired 1,386.834 phantom stock units.
• The transaction occurred on March 27, 2026.
• Each phantom unit represents one phantom share of Pfizer common stock and was valued at $27.04.
• These units are part of deferred director's compensation and include dividend equivalents.
• The units will be settled in cash or common stock at Mr. Buckley's election upon his retirement from the Board.
• Following this transaction, Mr. Buckley beneficially owns a total of 16,704.585 phantom stock units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their beneficial ownership, even through deferred compensation, generally indicates confidence in the company's future prospects.

Positives

• Director Mortimer J. Buckley increased his beneficial ownership in Pfizer through the acquisition of phantom stock units, aligning his interests with shareholders.
• The acquisition is part of a deferred compensation plan, indicating a structured approach to executive remuneration.

Future Outlook

The phantom stock units will be settled in cash or common stock upon the director's retirement from the Board, representing a future obligation for the company.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions of equity-linked compensation, are common practice in the pharmaceutical industry to align director interests with long-term company performance. This specific transaction reflects a standard deferred compensation mechanism for board members.

Comparison to Industry Standards

• Deferred compensation plans involving phantom stock or restricted stock units are a standard practice for director remuneration across large-cap pharmaceutical companies like Johnson & Johnson, Merck, and Bristol Myers Squibb, aiming to retain talent and align interests.
• The structure, where units settle upon retirement, is typical for long-term incentive plans for non-employee directors, promoting sustained engagement.

Related Party Transactions

• The acquisition of phantom stock units by a director as part of deferred compensation can be considered a related party transaction, though it is a standard compensation mechanism.

Stakeholder Impact

• Shareholders: The transaction aligns the director's interests with shareholders, potentially fostering long-term value creation.

Next Steps

• The phantom stock units will be settled in cash or common stock at the director's election following his retirement from the Board of Directors.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of phantom stock units by a director as part of deferred compensation. While it shows continued alignment of interests, it does not present new information significant enough to warrant a change in investment recommendation for Pfizer Inc. based solely on this filing. It's a standard compensation event.

Keywords

Pfizer, PFE, Form 4, Insider Transaction, Phantom Stock Units, Director Compensation, Mortimer J. Buckley, Deferred Compensation